What Activigil Treats: Main Uses and Benefits

Activigil is commonly used to help manage symptoms related to systemic imbalance in conditions characterized by periods of heightened symptoms. Its primary role is addressing excessive daytime sleepiness (EDS) that significantly interferes with daily functioning.

The medication is generally applied across domains where additional symptomatic support is needed to address chronic sleep-wake disorders. This is relevant for supporting the functional alertness in patients with debilitating conditions like narcolepsy and chronic Shift Work Sleep Disorder (SWSD). It is also considered relevant for easing symptoms that interfere with daily comfort when a patient still experiences residual sleepiness despite receiving optimal primary treatment for Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS).

The principal goal is to contribute to the management of functional alertness, which helps ease the overall symptom load.

Quick Fact: Relief for Excessive Sleepiness

The medicine may provide support for functional stability, helping patients cope more steadily with symptom fluctuations and supporting general well-being during symptomatic phases related to chronic sleep disorders.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Activigil?

Eligibility for Activigil (Modafinil) is strictly defined by government regulatory documents, focusing on patient age, pre-existing health conditions, and physiological status.

---

Contraindicated and Restricted Use

Classification	Population Group
Contraindicated	Patients with known hypersensitivity to modafinil, armodafinil, or any component.
	Patients with a history of Left Ventricular Hypertrophy (LVH) or Cor Pulmonale.
	Pregnant females and females attempting conception.
Not Recommended	Children and adolescents (under 17/18 years of age) for any indication.
	Breastfeeding mothers and patients with uncontrolled moderate to severe hypertension or cardiac arrhythmias.

---

Conditional Eligibility

Activigil is approved for adults (18 years and older) with specific sleep-wake disorders. Use is conditional for certain patient groups:

• Severe Hepatic Impairment: Requires a mandatory dose reduction to one-half the usual dose.
• Females of Reproductive Potential: Must use effective non-hormonal contraception during treatment and for two months after discontinuation.
• Older Adults (Geriatric): Requires the use of lower initial doses and careful monitoring.
• Psychiatric History: Patients with a history of psychosis, mania, or severe anxiety should be treated with caution and monitored closely.

Activigil Interactions with other medicines and products

Activigil’s official interaction profile is characterized by its influence on hepatic drug-metabolizing enzymes. This results in pharmacokinetic interactions that alter the systemic exposure of co-administered medicines.

Pharmacokinetic Alterations

The drug is documented as a modest inducer of CYP3A4/5 and a reversible inhibitor of CYP2C19.

• Reduced Exposure: Co-administration may decrease the effectiveness and circulating levels of medications metabolized by CYP3A4/5. This includes Steroidal Contraceptives (pills, patches, rings), Cyclosporine, and certain benzodiazepines such as Triazolam or Midazolam. The reduction in contraceptive effectiveness requires the use of alternative or concomitant non-hormonal birth control methods.
• Increased Exposure: Inhibition of CYP2C19 may lead to increased circulating levels of its substrates, including Diazepam, Omeprazole, and Phenytoin.
• Anticoagulants: Due to the potential suppression of CYP2C9, the clearance of Warfarin may be reduced. Regulatory documents require regular monitoring of prothrombin times, particularly during the initial two months of therapy or following dosage changes.

Interaction-Related Constraints and Requirements

• Contraception Timing: Alternative or concomitant non-hormonal contraception methods must be used during therapy and for two months after discontinuation of Activigil to ensure effective coverage.
• Alcohol: Patients are formally advised to avoid the consumption of alcohol due to the possibility of unstudied pharmacodynamic interaction.
• Population Note: Individuals who are CYP2D6 poor metabolizers may experience increased circulating levels of certain CYP2D6 substrates that rely on the inhibited CYP2C19 pathway for ancillary elimination.

How Activigil Works

Key Arousal and Vigilance Systems Modulated

This drug acts within the central nervous system to modulate activity in pathways that regulate arousal by influencing several key neurochemical systems. It exerts its primary effects by interfering with the clearance of the neurotransmitter dopamine, specifically by inhibiting the Dopamine Transporter (DAT) protein. This action prolongs the presence of dopamine in the synapse, which enhances dopaminergic neurotransmission in arousal-controlling regions.

Multi-Target Pathway Modulation

Activigil also engages the orexin (hypocretin) system, which functions to stabilize regulatory signals for the sleep-wake cycle. Furthermore, it modulates the activity of other wake-promoting messengers like histamine and norepinephrine, while potentially reducing the activity of GABA, the brain’s main inhibitory chemical. This combined, multi-target approach increases excitatory signaling within brain regions associated with arousal.

Resulting Physiological State

The collective action across these systems—increasing dopamine and orexin activity while influencing inhibitory signals—shifts the overall neurochemical balance toward a state of heightened excitability. This mechanism influences central nervous system activity, resulting in a state characterized by heightened arousal and vigilance.

How Activigil is Used

The administration of Activigil (Modafinil) follows established guidelines focusing strictly on specific dosage ranges, timing, and conditions of use. The medicine is supplied as an oral tablet and must be swallowed whole.

Administration and Standard Dosing

The standard starting dose for adults with Narcolepsy, Obstructive Sleep Apnea (OSA), and Shift Work Sleep Disorder (SWSD) is typically 200 mg once daily. While doses up to 400 mg per day have been used, they may not offer additional benefit over the standard dose. The total daily dose may be administered as a single dose or divided into two doses (e.g., morning and noon) for conditions like Narcolepsy or OSA.

Timing of administration depends on the specific use. For Narcolepsy and OSA, the dose is generally taken once a day in the morning. In contrast, for SWSD, the administration is timed approximately one hour prior to the start of the work shift. Activigil can be taken with or without food.

Population-Specific Use and Context

Clinical guidelines indicate dose adjustments for certain patient groups. For individuals with severe hepatic impairment (severe liver damage), the dose should be reduced by one-half, typically to 100 mg daily. For older adults (over 65), a lower starting dose is also typically advised. Use is not recommended for individuals under 18 years of age.

In the context of Obstructive Sleep Apnea, Activigil serves an adjunctive role; its use should supplement primary treatment with Continuous Positive Airway Pressure (CPAP). Long-term use involves a requirement for periodic re-evaluation of the need for continued treatment.

Activigil: Research Evidence Overview

The clinical understanding of Activigil is based on short-term randomized controlled trials (RCTs) across three main areas of research. These studies primarily examine the medicine’s influence on excessive daytime sleepiness (EDS) using objective measures, such as the Maintenance of Wakefulness Test (MWT), and patient-reported scales for subjective sleepiness (Epworth Sleepiness Scale, ESS).

Evidence Focus by Indication

For narcolepsy, core efficacy trials focused on adults and typically lasted 9 to 12 weeks. Data show patterns related to an observed increase in wakefulness time and changes in subjective sleepiness.

Research for Shift Work Sleep Disorder (SWSD) consists of short-term RCTs that monitored outcomes related to episodic changes in alertness during work hours. Findings described patterns related to changes in subjective sleepiness and sustained attention when compared to placebo.

For Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS), studies have evaluated Activigil as a compound for patients experiencing significant residual EDS despite adhering to their primary treatment (such as CPAP). Research indicates the focus is strictly on residual sleepiness and not on the underlying breathing disorder itself.

Key Evidence Gaps and Uncertainties

Across all indications, the evidence is largely derived from short-term trials. Long-term effects are not fully established, and follow-up durations were limited for core efficacy assessments.

Further data are still emerging for certain populations, including children and adolescents, who were evaluated in specific narcolepsy studies. Critically, the evidence contributes to understanding sleepiness but does not determine outcomes for other associated symptoms, such as cataplexy in narcolepsy. Due to the varied nature of the studies, consensus on the evidence for certain conditions may vary among international regulatory bodies.

Key Studies & References Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy (NCT00107796)

Common questions about Activigil (FAQ)

Q: Does Activigil cause weight gain or weight loss?

According to official product information, a decrease in appetite, or anorexia, is listed as a reported adverse reaction of Activigil. However, substantial changes in body weight are not categorized among the most frequently observed side effects in the regulatory documentation.

---

Q: Is Activigil a controlled substance?

Yes, the active substance in this medicine is classified as a Schedule IV controlled substance by the US Drug Enforcement Administration (DEA). This classification indicates that the drug has an accepted medical use but also possesses a potential for abuse, which is why it is strictly regulated.

---

Q: Are there any foods or supplements I should avoid with Activigil?

Regulatory sources formally advise patients to avoid the consumption of alcohol while taking this medicine due to the possibility of unstudied effects. Official instructions also state that Activigil can be taken either with or without food. Regulatory documents do not specifically prohibit other common foods or supplements.

---

Q: Does Activigil require special monitoring or blood tests?

Official documents mandate careful monitoring for certain patient groups. Specifically, patients taking Warfarin require regular monitoring of blood clotting times (prothrombin times). Dose adjustments and close observation are also mandated in official labeling for individuals with severe liver damage (hepatic impairment).

---

Q: What does 'contraindication' mean in relation to Activigil?

A contraindication describes a specific condition or characteristic in which a medicine is not to be used by a patient. According to official documents, this is because using the drug under these specific circumstances may pose a risk that is significantly greater than any potential benefit.

---

Q: Are the effects of Activigil the same for everyone?

Official pharmacological information indicates that effects can vary between individuals due to differences in how their bodies process the drug. For instance, specific genetic profiles, such as being a CYP2D6 poor metabolizer, can influence the amount of the drug circulating in the body. Clinical studies focus on outcomes for large groups of people, not individual guaranteed effects.

---

Q: What is the typical course of treatment with Activigil?

According to the official instructions, Activigil is intended to help improve wakefulness. However, regulatory documents state that physicians must periodically re-evaluate whether continued use of the medicine is still appropriate for the patient. Official prescribing information does not specify a maximum duration for treatment.

---

Q: How quickly should I notice the effects of Activigil?

Regulatory studies show that the highest concentration of the active substance in the bloodstream, known as the peak level, is generally reached about 2 to 4 hours after a dose is taken. This measurement indicates when the concentration of the drug is highest in the bloodstream.

---

Q: How long does the effect of one dose of Activigil last?

The duration of the drug's presence in the body is characterized by its elimination half-life. Official pharmacological data indicates that the main active substance has a half-life of approximately 15 hours. This refers to the time it takes for the concentration of the medicine in the bloodstream to decrease by half.

---

Q: Is it possible to become dependent on Activigil?

Studies documented in the official labeling have noted that the drug has an abuse potential. It is described as being capable of producing psychoactive and euphoric effects. Due to these characteristics, the drug is regulated as a controlled substance, and official guidelines advise caution when the medicine is considered for individuals with a history of substance abuse.

---

Q: Does Activigil have a withdrawal period when stopping it?

Official data from clinical trials indicate that withdrawal symptoms have not been consistently observed upon stopping the medicine. Despite this finding, official guidelines advise that patients be monitored for potential signs of behavioral changes following discontinuation.

---

Q: Is there a generic version of Activigil available?

Yes, the active substance within Activigil, which is Modafinil, is available in generic form.

---

Q: Does taking Activigil impact my ability to drive or operate machinery?

Regulatory documents state that this medicine may influence a person's ability to drive or operate machinery. This is due to potential adverse reactions such as dizziness or blurred vision which can affect alertness and coordination.

---

Q: What happens if I accidentally take more Activigil than prescribed?

Documented symptoms of overdose are detailed in the official label. These may include excitement, agitation, insomnia, palpitations, anxiety, and chest pain.

---

Q: Why does Activigil need to be taken consistently?

The medicine is studied and intended to support sustained wakefulness. Maintaining a consistent concentration of the drug in the body supports the observed effects on arousal and vigilance.

---

Q: How long has Activigil been on the market?

The active substance found in Activigil, which is modafinil, received its initial regulatory approval for use in the United States in 1998. This is when the medication was first introduced for prescription use.

---

Q: Is Activigil approved in countries outside of the US?

The active substance, Modafinil, is approved and available for specific medical uses in numerous international territories. This includes countries within the European Union and the United Kingdom, according to their respective regulatory bodies.

---

Q: What is the risk of overdose with Activigil?

Official product information addresses the potential for overdose with Activigil. Documented symptoms associated with overdose include excitement, anxiety, and changes in heart rhythm.

---

Q: Can Activigil be used with anti-depressant medications?

Regulatory documents describe the potential for interactions between Activigil and certain anti-depressant medicines. These interactions can occur because Activigil influences specific drug-metabolizing enzymes in the liver, which may alter the concentration of the anti-depressant in the body.

---

Q: Does Activigil make you feel 'high'?

Official labeling describes the drug as having the potential to produce psychoactive effects, including euphoria. This potential is why the medicine is categorized as a controlled substance and is monitored for its potential for misuse.

---

Q: Is it normal to feel a change in appetite when starting Activigil?

A change in appetite is a documented adverse reaction. A decrease in appetite, medically referred to as anorexia, is listed among the reported side effects in the official product information.

---

Q: Why do official documents emphasize that Activigil is not a cure?

Regulatory bodies describe the medicine as a way to help control symptoms associated with sleep disorders. Official documents clarify that Activigil does not cure the underlying condition but rather addresses the symptom of excessive daytime sleepiness.

---

Q: Is it normal if Activigil seems less effective after a few months?

The efficacy of the medicine is established based on short-term clinical trials. For continued treatment, the need for physicians to periodically re-evaluate the treatment course is a regulatory requirement.

How to Store and Dispose of Activigil

Activigil (modafinil) tablets must be stored at Controlled Room Temperature (CRT), defined as 20C to 25C (68F to 77F). The medicine should be kept in the original container and stored away from excess heat and moisture to maintain its stability.

Storage and Handling Requirements

Requirement Type	Condition
Temperature	20C to 25C (CRT)
Protection	Store out of the sight and reach of children.
Container	Keep in the original, tightly closed container.

Disposal Instructions

Unused or expired Activigil should not be disposed of via household waste or flushed down the toilet. As a controlled substance, the product must be discarded according to local requirements for pharmaceutical waste, typically by returning it to a pharmacy or a designated collection point.